Parkin Antibody (N-term) Blocking peptide
€363.00
In stock
SKU
AC-BP6402a
Background:
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known; however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function.
Other Names:
E3 ubiquitin-protein ligase parkin, 632-, Parkinson juvenile disease protein 2, Parkinson disease protein 2, PARK2, PRKN
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6402a was selected from the Parkin region of human PARK2 (Parkin). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: PRKN (HGNC:8607)
Gene ID: 5071
Primary Accession: O60260
Other Accession: NP_004553
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known; however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function.
Other Names:
E3 ubiquitin-protein ligase parkin, 632-, Parkinson juvenile disease protein 2, Parkinson disease protein 2, PARK2, PRKN
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6402a was selected from the Parkin region of human PARK2 (Parkin). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: PRKN (HGNC:8607)
Gene ID: 5071
Primary Accession: O60260
Other Accession: NP_004553
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review